New combo therapy hopes to help weaker lung cancer patients
NCT ID NCT04297605
First seen Feb 12, 2026 · Last updated Apr 25, 2026 · Updated 7 times
Summary
This study tests a combination of one chemotherapy drug and the immunotherapy pembrolizumab for people with advanced non-small cell lung cancer who have a lower performance status (ECOG PS 2), meaning they need to rest up to half the day. The goal is to see if this treatment is safe and tolerable, and whether it can shrink tumors. About 28 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Rochester
NOT_YET_RECRUITINGRochester, New York, 14642, United States
-
University of Rochester
RECRUITINGRochester, New York, 14642, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.